JERUSALEM Oramed Pharmaceuticals has finished a mid-stage clinical trial of a pill-based treatment for Type 2 diabetes, the Israeli drug maker announced Thursday.
The company expects to report results from the phase 2b trial of the oral insulin capsule ORMD-0801 within the next few weeks. The trial took place at five locations in South Africa.
“The completion of the phase 2b clinical trial for ORMD-0801 is a significant milestone for Oramed,” Oramed CEO Nadav Kidron stated. “We are especially thankful for the dedication of all the investigators who participated in the study.”